BHVN - Biohaven Ltd.
Pre-market:
| Previous close | 20.73 |
| Open | 21.15 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's range | 20.03 - 22.05 |
| 52-week range | 5.54 - 22.05 |
| Volume | |
| Avg. volume | 978,590 |
| Market cap | 1.482B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -10.63 |
| Earnings date | 03 Aug 2023 - 07 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 25.80 |
Motley FoolWhy Biohaven Stock Caught Fire This Week
Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain was sparked by the company's research and development day presentation held on Wednesday. Highlights from Biohaven's presentation include the unexpected Food and Drug Administration (FDA) regulatory filing for the experimental spinocerebellar ataxia type 3 drug troriluzole, status updates on its closely watched epilepsy program, and a clinical strategy overview for its newly acquired neuroinflammatory asset BHV-8000.
ZacksBiohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates
At its R&D Day, Biohaven (BHVN) provides updates on its pipeline. It also announced submission of a regulatory filing seeking approval for troriluzole in SCA3, an ultra-rare disorder.
PR NewswireBiohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating diseases, including ultra-rare disorders, will provide an overview of clinical progress, regulatory updates, and pipeline developments at an in-person R&D Day today, concurrently with the Yale Ventures' Innovation Summit 2023 taking place on May 31-June 1. Members of Biohaven's senior managem
- PR Newswire
Biohaven to Present R&D Day at Yale School of Management
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating diseases, including ultra-rare disorders, will provide an overview of its platforms and pipeline at an in-person Research and Development (R&D) Day taking place on May 31 in New Haven, CT, concurrently with the Yale Ventures Innovation Summit 2023. Members of Biohaven's senior management team
- PR Newswire
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating neurological and neuropsychiatric diseases, including ultra-rare disorders, today reported financial results for the first quarter ended March 31, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.
Simply Wall St.Is Biohaven (NYSE:BHVN) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
PR NewswireBiohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company, today announced that Nick Kozauer, M.D. has joined its executive leadership team as Senior Vice President for Clinical Development and Regulatory Strategy.
ZacksIs Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?
Here is how Biohaven Ltd. (BHVN) and Hologic (HOLX) have performed compared to their sector so far this year.
- Simply Wall St.
Bullish Biohaven Ltd. (NYSE:BHVN) insiders filled their treasuries with US$37m worth of stock over last year
Quite a few insiders have dramatically grown their holdings in Biohaven Ltd. ( NYSE:BHVN ) over the past 12 months. An...
- PR Newswire
Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments
Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating neurological and neuropsychiatric diseases, including ultra-rare disorders, today reported financial results for the fourth quarter ended December 31, 2022, and provided a review of recent accomplishments and anticipated upcoming milestones. For periods prior to the October 3
- Zacks
Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders
Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.
- PR Newswire
Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders
Biohaven Ltd. (NYSE: BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. BHV-8000 (previously TLL-041) was licensed from Hangzhou Highlightll Pharmaceutical Co. Ltd. (Highlightll) and Biohaven anticipates advancing the agent into a Phase 1 study in 2023.
- PR Newswire
Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
Biohaven Ltd. (NYSE: BHVN) announced today that it will present an oral and poster presentation demonstrating the preclinical efficacy and initial Phase 1 safety and tolerability of BHV-7000, a novel activator of heteromeric Kv7.2/7.3 potassium channels, on the 2023 American Society for Experimental Neurotherapeutics Annual Meeting (ASENT 2023) virtual platform, taking place March 13-15, 2023. The presentation and poster, titled "Discovery and characterization of BHV-7000: a novel KV7.2/7.3 acti
ZacksPfizer (PFE) Gets FDA Nod for Migraine Nasal Spray Zavzpret
Zavzpret (zavegepant) is now part of Pfizer's (PFE) migraine drugs portfolio with the 2022 acquisition of Biohaven. Zavzpret provides migraine patients access to a fast-acting pain-relief option.
ZacksWhy Earnings Season Could Be Great for Biohaven (BHVN)
Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- PR Newswire
Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy
Biohaven Ltd. (NYSE: BHVN; "Biohaven") announced today that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for taldefgrobep alfa, a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA). Fast Track designation enables important new drugs to reach patients earlier by facilitating more frequent communications with the FDA and expeditious review of a drug which treats a serious condition and fills an unmet medical need. Biohaven previ
- PR Newswire
Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference
Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Tuesday, January 10, 2023 at 7:30 am (PT).
ZacksIs Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
Here is how Biohaven Ltd. (BHVN) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
- Simply Wall St.
Biohaven Ltd.'s (NYSE:BHVN) market cap dropped US$151m last week; individual investors who hold 55% were hit as were institutions
A look at the shareholders of Biohaven Ltd. ( NYSE:BHVN ) can tell us which group is most powerful. The group holding...
ZacksAfter Plunging 13% in 4 Weeks, Here's Why the Trend Might Reverse for Biohaven Ltd. (BHVN)
Biohaven Ltd. (BHVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ZacksHow Much Upside is Left in Biohaven Ltd. (BHVN)? Wall Street Analysts Think 54%
The average of price targets set by Wall Street analysts indicates a potential upside of 53.5% in Biohaven Ltd. (BHVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Zacks
Biohaven Ltd. (BHVN) Reports Q3 Loss, Misses Revenue Estimates
Biohaven Ltd. (BHVN) delivered earnings and revenue surprises of 30.83% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments
Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating neurological and neuropsychiatric diseases, including rare disorders, today reported financial results for the third quarter ended September 30, 2022, and provided a review of recent accomplishments and anticipated upcoming milestones. The reported financial results present,
- Investing.com
3 Hot Insider Trades, Plus Hedge Fund Moves: Coca-Cola, Biohaven, Carl Icahn
Coca-Cola (NYSE:KO) Director Herbert Allen bought $2 million worth of shares on Oct. 28: 33,200 shares at $60.1793 apiece. Shares slipped 1% for the week.
- Zacks
Biohaven Ltd. (BHVN) Expected to Beat Earnings Estimates: Should You Buy?
Biohaven Ltd. (BHVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.